XNAS · Healthcare · Biotechnology
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-03 | Q2 2026 | -1.22 | -1.14 | +6.56% | $25.1M | ✅ Beat | +0.05% | +0.47% | — |
| 2026-05-07 | Q1 2026 | -1.23 | -1.23 | +0.00% | $10.3M | ➖ Inline | -1.13% | -11.91% | -24.30% |
| 2026-02-26 |
| Q4 2025 |
| -1.37 |
| -1.29 |
| +5.84% |
| $6.2M |
| ✅ Beat |
| +0.11% |
| -11.07% |
| -23.02% |
| 2025-11-06 | Q3 2025 | -1.26 | -1.38 | -9.52% | $143,000 | ❌ Miss | — | — | — |
| 2025-02-27 | Q4 2024 | -0.89 | -0.88 | +1.12% | $0 | ✅ Beat | +7.74% | +2.71% | +0.99% |
| 2024-11-12 | Q3 2024 | -0.91 | -0.96 | -5.49% | $0 | ❌ Miss | +0.24% | -6.14% | -5.38% |
| 2024-02-28 | Q4 2023 | -0.86 | -0.90 | -4.65% | $0 | ❌ Miss | -4.26% | +1.78% | +8.82% |
| 2023-11-07 | Q3 2023 | -0.91 | -1.01 | -10.99% | $346,000 | ❌ Miss | -3.62% | -2.95% | +13.41% |
Showing last 8 quarters.